Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant
Lyle Feinstein(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Rainer Storb(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Monic J. Stuart(United States Department of Veterans Affairs), Stephen J. Forman(City Of Hope National Medical Center), Dietger Niederwieser(Leipzig University of Applied Sciences), Edward Agura(Baylor University Medical Center), Thomas R. Chauncey(City Of Hope National Medical Center), Ute Hegenbart(Heidelberg University), Brenda M. Sandmaier(University of Washington), Peter A. McSweeney(Mesoblast (United States)), Karl G. Blume(City Of Hope National Medical Center), Michael B. Maris(Colorado Blood Cancer Institute), Michael A. Pulsipher(Primary Children's Hospital), Theodore A. Gooley(Leipzig University), David G. Maloney(Fred Hutch Cancer Center)
Cited by 33
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k